Breast cancer endocrine therapy adherence in health professional shortage areas: Unique effects on patients with mental illness

被引:4
|
作者
Haskins, Cole B. [1 ,2 ,3 ]
McDowell, Bradley D. [4 ]
Carnahan, Ryan M. [1 ]
Fiedorowicz, Jess G. [1 ,5 ,6 ,7 ]
Wallace, Robert B. [1 ]
Smith, Brian J. [4 ,8 ]
Chrischilles, Elizabeth A. [1 ]
机构
[1] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA
[2] Univ Iowa, Med Scientist Training Program, Iowa City, IA USA
[3] Univ Colorado, Dept Psychiat, Aurora, CO USA
[4] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
[5] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
[6] Ottawa Hosp, Ottawa, ON, Canada
[7] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[8] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA
关键词
Mental illness; Breast cancer; Adherence; Access to care; Endocrine therapy; Shortage area; ADJUVANT HORMONAL-THERAPY; PRIMARY-CARE; MEDICATION ADHERENCE; CLINICAL-PRACTICE; DEPRESSION; NONADHERENCE; WOMEN; DISCONTINUATION; SCHIZOPHRENIA; MANAGEMENT;
D O I
10.1016/j.jpsychores.2020.110294
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Evaluate whether breast cancer endocrine therapy adherence is affected by access to primary and mental health care, particularly among at-risk patients with mental illness. Methods: The study included 21,892 SEER-Medicare women aged 68 or older with stage I-IV ER+ breast cancer, 2007 to 2013. Patient home counties during breast cancer diagnosis, if evaluated for HPSA care shortage status, were categorized as least, moderate, or highest shortage; unevaluated counties (no known shortage) were a fourth category. Endocrine therapy initiation and discontinuation were analyzed with Cox regression, and daily adherence with longitudinal linear regression. Results: After multivariate adjustment, patients in high primary care shortage counties were less likely to initiate endocrine therapy, reference least shortage [HR 0.92 (95% CI 0.86-0.97)]. Unevaluated counties had more oncologists per capita, fewer residents below the federal poverty level, and higher incomes. Mental health shortages were not associated with outcomes, however subgroups living in unevaluated counties were less likely to discontinue: patients with bipolar and psychotic disorders [discontinuation HR 0.35 (95% CI 0.17-0.73)], substance use [HR 0.48 (95% CI 0.24-0.95)], anxiety disorders [HR 0.56 (95% CI 0.35-0.90)]. Conclusions: Poor primary care access was associated with a lower likelihood of initiating endocrine therapy but living in counties without established mental health shortages may reduce the harmful association between mental illness and incomplete treatment receipt. Patients with mental illness may be more equipped to complete cancer treatment if given better mental health care access, suggesting a need for care coordination between primary and mental health care.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Adjuvant endocrine therapy in patients with breast cancer: Relationship between side effects, quality of life and treatment adherence
    Tavares, A.
    Mesquita, A.
    Magalhaes, D.
    Salgado, M.
    Braga, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S441 - S441
  • [32] Endocrine therapy adherence, side effects, and risk perception among racially diverse breast cancer patients.
    Wheeler, Stephanie B.
    Murphy, Caitlin C.
    Reeder-Hayes, Katherine Elizabeth
    Earp, Jo Anne
    Carey, Lisa A.
    Olshan, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] The effects of adjuvant endocrine therapy on bone health in women with breast cancer
    Ramchand, Sabashini K.
    Cheung, Yee-Ming
    Yeo, Belinda
    Grossmann, Mathis
    JOURNAL OF ENDOCRINOLOGY, 2019, 241 (03) : R111 - R124
  • [34] IDENTIFYING ADHERENCE BARRIERS TO ORAL ENDOCRINE THERAPY (OET) AMONG BREAST CANCER PATIENTS
    Paranjpe, R.
    Trivedi, M.
    Abughosh, S.
    VALUE IN HEALTH, 2018, 21 : S35 - S35
  • [35] Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients
    Woolpert, Kirsten M.
    Schmidt, Julie A.
    Ahern, Thomas P.
    Hjorth, Cathrine F.
    Farkas, Dora K.
    Ejlertsen, Bent
    Collin, Lindsay J.
    Lash, Timothy L.
    Cronin-Fenton, Deirdre P.
    BREAST CANCER RESEARCH, 2024, 26 (01) : 59
  • [36] Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients
    Arriola, Kimberly R. Jacob
    Mason, Tamara A.
    Bannon, Kari Ann
    Holmes, Carol
    Powell, Cecil Lamonte
    Horne, Kandra
    O'Regan, Ruth
    PATIENT EDUCATION AND COUNSELING, 2014, 95 (01) : 98 - 103
  • [37] Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings
    Chlebowski, Rowan T.
    Kim, Jisang
    Haque, Reina
    CANCER PREVENTION RESEARCH, 2014, 7 (04) : 378 - 387
  • [38] Endocrine therapy for male breast cancer: rates of toxicity and adherence
    Visram, H.
    Kanji, F.
    Dent, S. F.
    CURRENT ONCOLOGY, 2010, 17 (05) : 17 - 21
  • [39] Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer
    Wassermann J.
    Rosenberg S.M.
    Current Breast Cancer Reports, 2017, 9 (2) : 100 - 110
  • [40] Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
    Reeder-Hayes, Katherine E.
    Troester, Melissa A.
    Wheeler, Stephanie B.
    ONCOLOGIST, 2021, 26 (11): : 910 - 915